Daily Stock Analysis, ACHN, Achillion Pharmaceuticals Inc, priceseries

Achillion Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.27
Close
4.27
High
4.36
Low
4.17
Previous Close
4.27
Daily Price Gain
0.00
YTD High
4.74
YTD High Date
Feb 16, 2017
YTD Low
3.94
YTD Low Date
Jan 31, 2017
YTD Price Change
0.16
YTD Gain
3.89%
52 Week High
10.06
52 Week High Date
Jun 9, 2016
52 Week Low
3.78
52 Week Low Date
Nov 3, 2016
52 Week Price Change
-2.63
52 Week Gain
-38.12%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 18. 2015
9.81
Jan 5. 2016
10.31
10 Trading Days
5.10%
Link
LONG
Apr 12. 2016
8.12
Apr 29. 2016
8.59
13 Trading Days
5.78%
Link
LONG
May 20. 2016
8.42
Jun 13. 2016
9.31
15 Trading Days
10.59%
Link
Company Information
Stock Symbol
ACHN
Exchange
NasdaqGS
Company URL
http://www.achillion.com
Company Phone
203-624-7000
CEO
Milind S. Deshpande
Headquarters
Connecticut
Business Address
300 GEORGE STREET, NEW HAVEN, CT 06511
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001070336
About

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally.

Description

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor, which has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor that is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and one additional systemic ultra-rare disease; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally; and license and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.